Abbott Laboratories (ABT) Earnings Date & Reports

Key Takeaways

• Abbott reported second-quarter 2026 sales of $12.59 billion, up 13.0% on a reported basis and 4.8% on a comparable basis.
• Adjusted diluted EPS (earnings per share) came in at $1.31, topping the consensus estimate of roughly $1.28, while GAAP (Generally Accepted Accounting Principles) diluted EPS was $0.53.
• Management raised its full-year 2026 adjusted EPS guidance to $5.45–$5.60, up from a prior range of $5.38–$5.58.
• The company reaffirmed full-year comparable sales growth guidance of 6.5% to 7.5%.
• Diagnostics revenue surged 42.3% on a reported basis, reflecting the March 2026 acquisition of Exact Sciences.
• Abbott returned $2.1 billion to shareholders during the quarter through dividends and share repurchases.

Earnings Context and Why It Matters

Abbott's diversified healthcare portfolio spans medical devices, diagnostics, nutrition, and established pharmaceuticals, making its quarterly results a broad read on global healthcare demand. The second-quarter report carries added significance because it is the first full quarter to include Exact Sciences, a cancer diagnostics company Abbott acquired on March 23, 2026. That deal reshapes the diagnostics segment and adds a high-growth cancer-screening franchise to the mix. Investors were also watching whether Abbott could sustain margin expansion while managing headwinds in nutrition, which has faced strategic pricing actions and volume pressure. The results offer an important checkpoint on management's ability to deliver the sales and earnings acceleration it has guided for the back half of the year.

Reported Results

Abbott reported second-quarter 2026 sales of $12.59 billion, a 13.0% increase on a reported basis and a 4.8% increase on a comparable basis, which excludes the impact of foreign exchange and the Exact Sciences acquisition. Adjusted diluted EPS of $1.31 rose 4.0% year over year and beat the consensus estimate of approximately $1.28. GAAP diluted EPS was $0.53, reflecting specified items including acquisition-related charges.

By segment, Medical Devices sales rose 9.0% on a reported basis to $5.85 billion, with comparable growth of 8.4% led by electrophysiology (a heart rhythm treatment field) and rhythm management. Diagnostics revenue jumped 42.3% to $3.09 billion, lifted by Exact Sciences, while comparable growth was 2.9%. Established Pharmaceuticals grew 8.4% to $1.50 billion. Nutrition remained the weakest area, falling 3.1% to $2.14 billion, though sales improved sequentially.

Adjusted gross margin expanded 100 basis points to 58.0% of sales. Management raised full-year 2026 adjusted EPS guidance to $5.45–$5.60 and issued third-quarter adjusted EPS guidance of $1.38–$1.46, which was above the consensus of around $1.42.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking earnings events like Abbott's, it offers a streamlined way to surface comparable opportunities across the healthcare sector. Explore the AI Screener to refine your own research process.

Market Reaction and Investor Sentiment

Following the earnings announcement, Abbott shares rose 3.2% in pre-market trading, reflecting a positive reaction to the top-and-bottom-line beat and the raised full-year EPS guidance. Investor sentiment was buoyed by accelerating momentum in medical devices, double-digit cancer diagnostics growth, and the sequential improvement in nutrition. The reaffirmed comparable sales guidance and higher EPS outlook signaled management's confidence in second-half acceleration, which supported the constructive market response.

Forward Outlook and Key Factors to Monitor

Abbott enters the second half with clear growth drivers, but several factors will shape the next several quarters. The launch cadence of new products will be a key focus, including the international rollout of Libre Duo, the first dual glucose-ketone wearable sensor, and the full U.S. market release of the next-generation Volt 2.0 pulsed field ablation catheter.

In diagnostics, investors will watch whether cancer diagnostics momentum, led by mid-teens Cologuard growth, continues to accelerate, and whether the rapid and molecular diagnostics business stabilizes after a softer respiratory testing season. Core laboratory trends remain a useful indicator of underlying healthcare demand.

Nutrition will also remain in focus as management works to restore growth through pricing actions and new product launches, particularly in U.S. pediatric and adult segments. Margin expansion and the integration of Exact Sciences will be closely monitored, along with foreign exchange, which management expects to contribute about 1% to full-year sales.

Finally, the company has pointed to several product and regulatory milestones over the next 12 months, making the pace of approvals and reimbursement decisions an important catalyst to watch.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations